Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting

Diabetes Technology and Therapeutics

Volumn 11, Issue 6, 2009, Pages 353-359

  Bhushan, Rajat ^a   Elkind Hirsch, Karen E ^a   Bhushan, Madhu ^a   Butler, William J ^a   Duncan, Kelly ^a   Marrioneaux, Ory ^a  

^a Metabolic Center of Louisiana Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; DIURETIC AGENT; EXENDIN 4; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ABDOMEN; ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WEIGHT REDUCTION;

ADULT; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIURETICS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METABOLIC SYNDROME X; PEPTIDES; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; VENOMS;

EID: 67649854490     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2008.0090     Document Type: Article

References (38)

1. Reaven GM: Banting Lecture. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
2. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
3. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004;109:433-438.
4. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation, Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization, 1999.
5. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome: a new worldwide definition. Lancet 2005;366:1059-1062.
6. Balkau B, Deanfield JE, Despre's JP, Bassand JP, Fox KA, Smith SC, Jr, Barter P, Tan CE, Gaal LV, Wittchen HU, Massien C, Haffner SM: Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28: 364-376.
7. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-2581.
8. Lakka HM, Laaksonen DE, Lakka TT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716.
9. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066-3072.
10. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L: The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001;44:1148-1154.
11. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, Prina Cerai S, Pagano G, Cavallo-Perin P: Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004;27:2689-2694.
12. Bonora E, Targher G, Formentini G, Calcattera F, Lombardi F, Marinin L, Zenari F, Saggiani M, Poli S, Perbellini A, Rafaelli A, Gemma L, Santi L, Bonadonna RC, Muggeo M: The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetes subjects. Diabet Med 2004;21:52-58.
13. Sone H, Mizuno S, Fujii H, Yoshimura Y, Yamasaki Y, Ish-ibashi S, Katayama S, Saito Y, Ito H, Ohashi Y, Akanuma Y, Yamada N: Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care 2005;28:1463-1471.
14. Raufman JP: Bioactive peptides from lizard venoms. Regul Pept 1996;61:1-18.
15. Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D: Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005;7:467-477.
16. Egan JM, Clocquet AR, Elahi D: The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002;87:1282-1290.
17. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O: Effect of intrave- nous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004;53:2397-2403.
18. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD: Pharmacokinetics, pharmacody-namics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62:173-181.
19. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28: 1092-1100.
20. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635.
21. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091.
22. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124:136-145.
23. Resnick HE, Foster GL, Bardsley J, Ratner RE: Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006;29:531-537.
24. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-447.
25. Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon TH, Zhang B, Bicsak TA, Brodows, Kim DD: Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006;8:419-428.
26. Bhushan R, Elkind-Hirsch K, Bhushan M, Butler J, Duncan K, Marrioneaux O: Effects of exenatide therapy in patients with type 2 diabetes include reductions in HbA1c, weight, and cardiovascular risk factors in routine clinical practice [abstract]. Diabetes 2008;57(Suppl):2066.
27. John LE, Kane MP, Busch RS, Hamilton RA: Expanded use of exenatide in the management of type 2 diabetes. Diabetes Spectr 2007;20(1):59-63.
28. Thompson PD, Jeffery RW, Wing RR, Wood PD: Unexpected decrease in plasma high-density lipoprotein cholesterol with weight loss. Am J Clin Nutr 1979;32:2016-2021.
29. Williams PT, Stefanick ML, Vranizan KM, Wood PD: The effects of weight loss by exercise or by dieting on plasma high-density lipoprotein (HDL) levels in men with low, intermediate, and normal-to-high HDL at baseline. Metabolism 1994;43:917-924.
30. Wood PD, Stefanick ML, Williams PT, Haskell WL: The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N Engl J Med 1991;325:461-466.
31. Thompson PD, Yurgalevitch SM, Flynn MM, Zmuda JM, Spannaus-Martin D, Saritelli A, Bausserman L, Hebert PN: Effect of prolonged exercise training without weight loss on high-density lipoprotein metabolism in overweight men. Metabolism 1997;46:217-223.
32. Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA, Speizer FE, Manson JE: Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women: the Nurses' Health Study. Am J Epidemiol 1997;145:614-619.
33. Balkau B, Deanfield JE, Després JP, Bassand JP, Fox KA, Smith SC Jr, Barter P, Tan CE, Gaal LV, Wittchen HU, Massien C, Haffner SM: International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007;116: 1942-1951.
34. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K: Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-1493.
35. Colditz GA, Willett WC, Rotnitzky A, Manson JE: Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-486.
36. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289: 76-79.
37. Nielsen LL, Young AA, Parkes D: Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88.
38. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, HansenB, Denaro M:Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999;48:1026-1034.